Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Plasma miRNA profiling in patients with hepetocellular carcinoma and liver cirrhosis

ABSTRACT: Plasma miRNA profiling in patients with hepetocellular carcinoma and liver cirrhosis

PROVIDER: PRJNA1247971 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Plasma miRNA profiling in patients with hepetocellular carcinoma and liver cirrhosis

Project description:To evaluate the potential of circulating microRNAs as biomarkers for early hepetocellular carcinoma (HCC) screening, plasma miRNA profiles were compared between patients with HCC and liver cirrhosis (LC).

2025-06-12 | GSE294055 | GEO

Plasma miRNA profiling of nasopahryngeal carcinoma patients

Project description:We performed miRNA microarray analysis to find differentially expressed miRNAs between nasopharyngeal carcinoma patients and normal control subjects In this study, 20 nasopharyngeal carcinoma patients and 10 normal control subjects were selected to collect plasma samples and perform miRNA microarray profiling

2013-07-02 | E-GEOD-48442 | biostudies-arrayexpress

miRNA sequencing of serum exosomes from hepatocellular carcinoma and liver cirrhosis patients

Project description:miRNA sequencing of serum exosomes from hepatocellular carcinoma and liver cirrhosis patients

| PRJNA412166 | ENA

Plasma extracellular vesicle microRNAs reflecting the therapeutic effect of the CBP/β-catenin inhibitor PRI-724 in patients with liver cirrhosis

Project description:Plasma extracellular vesicle (EV) miRNA profile before and after the administration of PRI-724 in patients with liver cirrhosis

2024-03-20 | GSE250179 | GEO

Quantitative proteome analysis of plasma microparticles for characterization of HCV-induced hepatic cirrhosis and hepatocellular carcinoma

Project description:A quantitative label-free proteome analysis was performed using plasma samples from 22 hepatitis-C virus (HCV)-induced liver cirrhosis patients, 16 HCV-positive hepatocellular carcinoma patients with underlying cirrhosis and 18 healthy controls. Plasma microparticles (PMPS) were isolated using ultracentrifugation and analyzed via label-free LC-MS/MS. A quantitative label-free proteome analysis was performed using plasma samples from 22 hepatitis-C virus (HCV)-induced liver cirrhosis patients, 16 HCV-positive hepatocellular carcinoma patients with underlying cirrhosis and 18 healthy controls. Plasma microparticles (PMPS) were isolated using ultracentrifugation and analyzed via label-free LC-MS/MS.

2017-06-21 | PXD005777 | Pride

Quantitative proteome analysis of plasma microparticles for characterization of HCV-induced hepatic cirrhosis and hepatocellular carcinoma

2020-03-12 | MSV000085094 | MassIVE

Liver tissue miRNA profile before and after the administration of PRI-724 in patients with liver cirrhosis

Project description:The dataset analyzed in the report entitled Plasma extracellular vesicle microRNAs reflecting the therapeutic effect of the CBP/β-catenin inhibitor PRI-724 in patients with liver cirrhosis

2024-03-20 | GSE250272 | GEO

Plasma-derived extracellular vesicles from patients with liver cirrhosis and hepatocellular carcinoma

Project description:Quantitative label-free proteomic analysis of extracellular vesicles. A pool of isolated proteins from extracellular vesicles (EVs) was performed for each sample group, namely healthy participants (HP), liver cirrhosis (LC), and hepatocellular carcinoma (HCC), split into three biological replicates. Then, samples were digested with trypsin, and the peptides were subjected to Nano LC-MS/MS Analysis and Mass Spectrometry. Nine raw MS files were analyzed and searched against the human protein database based on the species of the samples using Maxquant. The parameters were set as follows: the protein modifications were carbamidomethylation (C) (fixed), oxidation (M) (variable); the enzyme specificity was set to trypsin; the maximum missed cleavage was set to 2; the precursor ion mass tolerance was set to 10 ppm, and MS/MS tolerance was 0.5 Da.

2024-07-09 | PXD047723 | JPOST Repository

Plasma miRNA profiling of nasopahryngeal carcinoma patients

Project description:We performed miRNA microarray analysis to find differentially expressed miRNAs between nasopharyngeal carcinoma patients and normal control subjects

2013-07-02 | GSE48442 | GEO

EGFR inhibition prevents liver cirrhosis and hepatocellular carcinoma

Project description:EGFR inhibition prevents liver cirrhosis and hepatocellular carcinoma

| PRJNA138519 | ENA